News for Reviva Pharmaceuticals Holdings, Inc. (RVPH)

On June 3, 2025, Reviva Pharmaceuticals (RVPH) received a maintained 'Buy' rating from analyst Jason Kolbert at D. Boral Capital. The analyst's rating remains u

Reviva Pharmaceuticals (RVPH) has successfully wrapped up a Phase 3 open-label extension (OLE) study, exploring the long-term effects of brilaroxazine in schizo

Reviva Pharmaceuticals (RVPH) announces positive results from a 1-year Phase 3 study on brilaroxazine for schizophrenia. The study shows a 35% discontin

”“ Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms ”“ ”“ Generally well-tolerated with l

”“ 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatm

Reviva Pharmaceuticals (RVPH) is making significant progress with its late-stage brilaroxazine program, gearing up for key developments in the near future. The

CUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. ( RVPH) (”œReviva” or the ”œCompany”), a late-stage pharmace

CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. ( RVPH) (”œReviva” or the ”œCompany”), a late-stage pharmace

On December 31, 2024, Schonfeld Strategic Advisors LLC (Trades, Portfolio) made a significant move by reducing its stake in Reviva Pharmaceuticals Holdings Inc

**media[531692]**

Investors with a lot of money to spend have taken a bearish stance on Reviva Pharmaceuticals RVPH. And retail traders should know. We noticed this today when ...

CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. ( RVPH) (”œReviva” or the ”œCompany”), a late-stage pharmaceu

New York-based Syntec Optics Holdings, Inc. (OPTX) is up over 167 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Shares of Mitek Systems, Inc. MITK rose sharply in today's pre-market trading after reporting better-than-expected fourth-quarter results. Mitek Systems report...

Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants

**media[493991]**

Reviva Announces Proposed Public Offering

”“ Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year ”“ ”“ Generally well-tolera

North Carolina-based Chimerix, Inc. (CMRX) is up over 163 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.